Canaccord Genuity has reiterated its Buy recommendation on Guardant Health, assigning a $125.00 price target to the shares of the diagnostics company. Guardant Health (NASDAQ:GH) was trading at $114.75, roughly 0.95% below its 52-week high of $120.74 at the time of the note.
The research firm issued the reaffirmation following Guardant Health's preliminary fourth-quarter 2025 results, which the company disclosed on Sunday, January 11. Canaccord said the preliminary results exceeded both the firm’s internal projections and the FactSet consensus. Canaccord attributed the outperformance to solid volume growth in the company’s Oncology business and in its Shield test offerings.
Alongside top-line performance, Guardant provided cash burn figures for Q4 2025. Canaccord interpreted those disclosures as consistent with the company’s stated trajectory toward achieving cash flow break-even by 2028.
Canaccord outlined several potential 2026 catalysts that could influence Guardant’s commercial and clinical momentum. Those items include:
- the possibility of Advanced Diagnostic Laboratory Test (ADLT) designation for the company’s Reveal product;
- recent and upcoming product launches;
- expanded clinical applications for Guardant360 (G360);
- continued advantages stemming from Guardant’s early position in blood-based colorectal cancer screening; and
- progress on multi-cancer detection initiatives.
Canaccord argued that Guardant’s shares remain undervalued given its established therapy selection franchise and ongoing development across minimal residual disease detection, colorectal cancer screening, and multi-cancer detection technologies.
Other research firms have recently adjusted their views and price targets on Guardant Health. Stifel raised its price target to $120 while maintaining a Buy rating, citing expectations for higher volume and average selling prices by 2026. Jefferies increased its target to $130 and highlighted the company’s valuation relative to projected 2026 sales. BTIG named Guardant as one of its top picks for 2026, pointing to catalysts such as Shield CRC and Shield MCED.
Regulatory and clinical developments have also reinforced Guardant’s positioning. The U.S. Food and Drug Administration approved Guardant360 CDx as a companion diagnostic for identifying patients with BRAF V600E-mutant metastatic colorectal cancer. That approval was supported by data from Pfizer’s Phase 3 BREAKWATER trial, which demonstrated improved outcomes for patients treated with encorafenib, cetuximab, and chemotherapy.
In addition to analyst activity and regulatory milestones, Guardant’s technology has begun to be deployed within hospital systems. Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome has launched an in-house liquid biopsy testing service that will use Guardant360 CDx technology to perform on-site testing for cancer patients, eliminating the need to send samples abroad.
Collectively, these operational, regulatory, and commercial developments underpin the recent analyst commentary and the reiterated Buy stance from Canaccord, while other firms have adjusted targets upward in light of expected volume, pricing improvements, and ongoing product momentum.